Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
20.68
-0.06 (-0.29%)
At close: Apr 10, 2026, 4:00 PM EDT
20.65
-0.03 (-0.15%)
Pre-market: Apr 13, 2026, 4:40 AM EDT
Zai Lab Employees
Zai Lab had 1,784 employees as of December 31, 2025. The number of employees decreased by 85 or -4.55% compared to the previous year.
Employees
1,784
Change (1Y)
-85
Growth (1Y)
-4.55%
Revenue / Employee
$257,935
Profits / Employee
-$98,395
Market Cap
2.33B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,784 | -85 | -4.55% | 1,784 | 0 |
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Sarepta Therapeutics | 835 |
| Ascentage Pharma Group International | 767 |
| ADMA Biologics | 647 |
| Syndax Pharmaceuticals | 298 |
| Celldex Therapeutics | 198 |
| Day One Biopharmaceuticals | 178 |
| Immunome | 177 |
ZLAB News
- 12 days ago - Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy - Business Wire
- 24 days ago - Insider Buying: Richard Gaynor Acquires Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 25 days ago - JP Morgan Lowers Price Target for Zai Lab (ZLAB) to $32 | ZLAB Stock News - GuruFocus
- 26 days ago - Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) - Business Wire
- 5 weeks ago - Insider Sell: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 5 weeks ago - Insider Sell Alert: Rafael Amado Sells 10,000 Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 6 weeks ago - Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight - GuruFocus
- 6 weeks ago - Zai Lab Ltd (ZLAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus